US OptionsDetailed Quotes
RIGL241220C31000
- 0.65
- +0.05+8.33%
15min DelayClose Dec 3 16:00 ET
0.65High0.65Low
0.65Open0.60Pre Close1 Volume10 Open Interest31.00Strike Price65.00Turnover81.71%IV17.01%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type0.2496Delta0.0668Gamma41.62Leverage Ratio-0.0457Theta0.0028Rho10.39Eff Leverage0.0185Vega
Rigel Pharmaceuticals Stock Discussion
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more freque...
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Let's break 30.+
27.+
Let's Get 30.+
25.+
Go, Go, Go!!!
No comment yet